You just read:

Canadian Agency for Drugs and Technologies in Health (CADTH) recommends provincial and publicly funded drug plans reimburse (Pr)Lucentis* to treat vision loss resulting from diabetic macular edema (DME)

News provided by

Novartis Pharmaceuticals Canada Inc.

Mar 28, 2012, 12:37 ET